T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy

Ignacio Melero, Ana Rouzaut, Greg Motz, George Coukos

Cancer Discovery · 2014 · 441 citations · 20 references

DOIFull text

Open access

Concepts

TL;DR

Cancer immunotherapy holds promise yet is constrained by tumor strategies that impair antigen presentation, lymphocyte activation, and homing through soluble mediators, vascular alterations, and immunosuppressive cells. The study investigates tumor‑exploited immunosuppressive mechanisms and evaluates emerging therapies that target lymphocyte trafficking. The authors analyze these pathways and assess therapeutic approaches designed to enhance lymphocyte infiltration into solid tumors. Published in Cancer Discovery, vol.

Abstract

Abstract Summary: Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK–cell activation, and T/NK–cell homing through soluble and cell-surface mediators, the vasculature, and immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells. However, many molecular mechanisms preventing the efficacy of antitumor immunity have been identified and can be disrupted by combination immunotherapy. Here, we examine immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under development to overcome them, focusing on lymphocyte traffic. Cancer Discov; 4(5); 522–6. ©2014 AACR.

References

20